Moderna and Merck Personalized Cancer Vaccine Succeeds in Phase 3 Trial

By Beth Mole · Ars Technica · 2026-10-22

Ars Technica reports that a combination of the mRNA-4157 vaccine and the immunotherapy drug Keytruda significantly improved survival outcomes for melanoma patients. The treatment uses synthetic mRNA tailored to the specific mutations found in an individual's cancer cells. This pe

Ars Technica reports that a combination of the mRNA-4157 vaccine and the immunotherapy drug Keytruda significantly improved survival outcomes for melanoma patients. The treatment uses synthetic mRNA tailored to the specific mutations found in an individual's cancer cells. This pe